ROAD TO THE CURE UPDATE APRIL 2015

THE SAN DIEGO BIOTECH COMPANY (SDBC) […ICBI technology was selected for publication in a very prestigious biotech journal that tracks emerging healthcare new technologies... “We are delighted that our technology became the subject of such a reputable report.”]

Alpha-Synuclein and Parkinson Disease

α-Synuclein is a very useful presynaptic neuronal protein involved in transmitting signal from one neuron to another. Unfortunately, individuals who have either gene duplication and/or mutation in alpha-synuclein gene are afflicted with Parkinson’s disease (PD).αα-Synuclein can contribute to PD pathogenesis in a number of ways, but it is generally thought that its aberrant soluble oligomeric conformations, termed protofibrils, are the toxic species that mediate disruption of cellular function and neuronal death leading to motor dysfunction. Figure 1 below outlines the role of α-Synuclein in causing two additional brain diseases: PD with Dementia (PDD) and Dementia with Lewy Bodies (DLB). Thus, α-Synuclein is an important pharmaceutical target and scientists all over the world have been trying to develop technologies to regulate the function of α-Synuclein to minimize patients’ debilitation.

What is ICBI doing to Prevent, Halt and Eliminate α-Synuclein Aggregation?

ICBI has already developed a blood-brain barrier permeable SMART Molecule for α-Synuclein, which has been tested in animals to specifically target aggregated α-Synuclein and Lewy body like deposits. This drug is ready to be tested in non-human primates and then humans. ICBI has developed SMART molecule for triple mutant A30P/A56P/ A76P of α-Synuclein. Isolation and purification will begin shortly. ICBI is also planning to develop a SMART Molecule for phosphorylated α-Synuclein at position S129. As soon as ICBI is able to buy this protein, development of a SMART Molecule will begin.

Roots Analysis Recognizes ICBI Blood-Brain Barrier Permeable Technology

ICBI technology was selected for publication in a very prestigious biotech journal known as the Roots Analysis. This journal tracks emerging healthcare new technologies and costs $2000 plus per copy. We are delighted that our technology became the subject of such a reputable report.

Hope For The Patients

Thus far the failure of most drugs to halt or cure Parkinson’s diseases has been due to one main reason: Inaccessibility of drugs to the brain. Fortunately, ICBI has developed a very powerful technology that has been unequivocally proven to traffic through the blood-brain barrier (BBB) reach the central nervous system. The rest is a matter of scaling up the production of all drug candidates to conduct pharmacology and establish therapeutic efficacy, which requires significant cash infusion. PRO proudly continues reporting advancements in ICBI and their scientist’s historic work to the Parkinson’s world. This remarkable science continues as they help you understand the never before possible, “real time”, reporting of creating the “Road To The Cure”, including imaging the proteins causing Parkinson’s in the brain of live mice and now primates.

We invite you to contact us if you want information about supporting or investing in The Parkinson’s Road To The Cure. We would be proud to make this important introduction and we continue to salute these scientists as they forge ahead!